DealsJul 31, 2026, 04:48 PM
aTyr Pharma Regains Global Rights to Efzofitimod
AI Summary
aTyr Pharma, Inc. announced the termination of its collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd., effective July 30, 2026. This mutual agreement follows Kyorin's earlier notice of termination without cause. As a result, aTyr Pharma has regained the exclusive rights to develop and commercialize efzofitimod in Japan, and now holds global rights for the product for all forms of interstitial lung disease. The companies also agreed on specific wind-down activities and the termination of other ancillary agreements.
Key Highlights
- aTyr Pharma and Kyorin Pharmaceutical mutually agreed to terminate their collaboration and license agreement.
- The termination of the Kyorin Agreement became effective on July 30, 2026.
- Exclusive rights to develop and commercialize efzofitimod in Japan reverted to aTyr Pharma.
- aTyr Pharma now holds global rights for efzofitimod for all forms of interstitial lung disease.
- The parties agreed on wind-down activities and termination of associated ancillary agreements.
Price Impact
More from ATYR